中国实验血液学杂志最新文献

{"title":"[Clinical Study of Dendritic Cell Vaccine as Maintenance Therapy for Acute Myeloid Leukemia].","authors":"Shan-Shan Qin, Yao Sun, Yu-Hang Li, Na Liu, Jiang-Wei Hu, Zhuo-Qing Qiao, San-Chun Lan, Jing Xie, Ying-Jie Liu, Jing-Wen Niu, Lei Wang, Liang-Ding Hu","doi":"10.19746/j.cnki.issn1009-2137.2026.04.010","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.010","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the safety of genetically modified dendritic cell (gmDC) vaccine as maintenance therapy in patients with favorable-risk acute myeloid leukemia (AML), and its long-term efficacy.</p><p><strong>Methods: </strong>A retrospective cohort study of patients with favorable-risk AML treated at the Fifth Medical Center of Chinese People's Liberation Army General Hospital from January 2013 to December 2023 was conducted. All patients achieved minimal residual disease (MRD) negativity after consolidation chemotherapy or autologous stem cell transplantation. Among them, 27 patients who received gmDC vaccine maintenance therapy were enrolled in the gmDC group, and 30 patients who received no maintenance therapy served as the control group during the same period. The study endpoints were safety, overall survival (OS), progression-free survival (PFS), and cumulative incidence of relapse (CIR).</p><p><strong>Results: </strong>The median follow-up of the patients was 41 months, all adverse events in the gmDC group were grade 1, and no grade ≥3 events occurred. The 3-year OS rate was 100% in the gmDC group, which was significantly higher than 76.9% in the control group (<i>P</i> <0.05). The 3-year PFS rate was 81.3% in the gmDC group, which was higher than 73.3% in the control group (<i>P</i> >0.05), showing a trend toward improvement that did not reach statistical significance. The 3-year CIR was 18.7% in the gmDC group, which was lower than 23.3% in the control group (<i>P</i> >0.05), showing a decreasing trend without statistical significance.</p><p><strong>Conclusion: </strong>In patients with favorable-risk AML, gmDC vaccine maintenance therapy demonstrates a favorable safety profile and significantly improves 3-year OS, but no significant improvement is observed in 3-year PFS and CIR.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1000-1005"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Study on the Mechanism of CDC20 Inducing Cytarabine Resistance in Acute Myeloid Leukemia Cells by Targeting Autophagy].","authors":"Shu-Min Ding, Jin-Yao Kan, Yan Wang, Si-Yuan Cui, Jing-Yi Wang, Rui-Rong Xu","doi":"10.19746/j.cnki.issn1009-2137.2026.04.004","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.004","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the role and mechanism of CDC20 in cytarabine (Ara-C) chemosensitivity of acute myeloid leukemia (AML) cells.</p><p><strong>Methods: </strong>AML cell lines (Kasumi-1 and THP-1) with stable <i>CDC20</i> overexpression or knockdown (shRNA) were established using lentiviral vectors. Cell viability and inhibition rates under Ara-C treatment (0, 0.25, 0.5, 1 μmol/L, 24 h) were assessed by the CCK-8 assay. Apoptosis was analyzed by flow cytometry. Protein expression of cleaved caspase-3, Bcl-2, LC3B, LC3B-II/LC3B-I ratio, p-AKT, and AKT was determined by Western blot. ROS levels were also measured. Autophagic activity was evaluated by transmission electron microscopy (autophagosome counting). The LC3B degradation pathway was investigated using cycloheximide (CHX) and MG132.</p><p><strong>Results: </strong>Compared with controls, <i>CDC20</i> overexpression significantly reduced Ara-C-induced cell growth inhibition and apoptosis (<i>P</i> < 0.05), indicating enhanced chemoresistance; whereas <i>CDC20</i> knockdown increased apoptosis and sensitivity. <i>CDC20</i> overexpression decreased LC3B protein levels and the LC3B-II/LC3B-I ratio, suppressing autophagy, while <i>CDC20</i> knockdown showed the opposite effects. CHX and MG132 assays confirmed that <i>CDC20</i> promoted LC3B degradation via the ubiquitin-proteasome pathway, independent of transcription. <i>CDC20</i> overexpression also increased p-AKT levels and reduced ROS generation, while <i>CDC20</i> knockdown had the opposite effect. Rapamycin reversed the apoptosis inhibition and drug resistance induced by <i>CDC20</i> overexpression.</p><p><strong>Conclusion: </strong>CDC20 promotes LC3B degradation via the ubiquitin-proteasome pathway to suppress autophagy, while concurrently activating AKT signaling and reducing ROS levels, thereby synergistically driving Ara-C resistance in AML cells.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"955-964"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research Progress on the Application of Single-Cell Sequencing Technology in Diffuse Large B-Cell Lymphoma --Review].","authors":"Alimire Maimaiti, Yan Li","doi":"10.19746/j.cnki.issn1009-2137.2026.04.046","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.046","url":null,"abstract":"<p><p>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Its high genomic and transcriptomic heterogeneity leads to significant differences in clinical phenotypes and prognosis. Traditional bulk sequencing techniques cannot fully resolve heterogeneity at the single-cell level and fail to reveal the interactions and dynamic changes between cells. The breakthrough progress of single-cell sequencing (SCS) technology has provided a new perspective for elucidating the pathogenesis of DLBCL. SCS technology accurately identifies hetero- geneous cell subpopulations at the single-cell level, systematically dissects cellular interactions within the tumor microe- nvironment (TME), reveals the complex changes of tumor cells, optimizes the prognostic evaluation system, and explores new breakthroughs in the study of novel therapeutic targets. This article systematically reviews the cutting-edge progress of SCS technology in DLBCL research, provides a theoretical basis for promoting precise treatment of the disease, and looks forward to the clinical application prospects of multi-omics and spatial transcriptomics technologies.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1235-1240"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy and Safety of Venetoclax Combined with Azacitidine versus Azacitidine Monotherapy in the Treatment of Higher-Risk Myelodysplastic Syndromes].","authors":"Luan Hu, Jing-Jing Guo, De-Peng Li, Ting-Ting Qiu","doi":"10.19746/j.cnki.issn1009-2137.2026.04.020","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.020","url":null,"abstract":"<p><strong>Objective: </strong>To compare the efficacy and safety of venetoclax (VEN) combined with azacitidine (AZA) regimen versus AZA monotherapy regimen in the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS).</p><p><strong>Methods: </strong>The clinical data of 62 patients with HR-MDS who were treated at the Affiliated Hospital of Xuzhou Medical University from April 2020 to June 2024 were retrospectively collected. According to the treatment regimen, the patients were divided into the combined therapy group (VEN plus AZA) and the monotherapy group (AZA alone). The efficacy, adverse reactions, and survival outcomes of the two groups were compared.</p><p><strong>Results: </strong>The overall response rate (ORR) of the combination therapy group was 79.2% (19/24), which was significantly higher than that of the monotherapy group (39.5%, 15/38) (<i>P</i>＜0.05). Among these responses, 45.8% (11/24) of patients in the combination therapy group achieved marrow complete remission (mCR), which was significantly higher than the 18.4% (7/38) in the monotherapy group (<i>P</i>＜0.05). The median number of cycles to response in the combination therapy group was 1 (range, 1-2), which was significantly shorter than the 2 (range, 1-3) cycles in the monotherapy group (<i>P</i>＜0.05). Regarding safety, the incidence rates of grade≥3 anemia and neutropenia in the combination therapy group were significantly higher than those in the monotherapy group (<i>P</i>＜0.05). Additionally, there were no statistically significant differences in the incidence rates of non-hematological adverse events (including gastrointestinal reactions, secondary infections, liver and kidney dysfunction, and allergic reactions) between the two groups (<i>P</i>＞0.05). Survival analysis revealed a median overall survival (OS) of 20.5 months in the combination therapy group, significantly longer than the 13.6 months in the monotherapy group (<i>P</i>＜0.05). Furthermore, the median progression-free survival (PFS) was 16.0 months in the combination therapy group, significantly longer than the 8.7 months in the monotherapy group (<i>P</i>＜0.05).</p><p><strong>Conclusion: </strong>The VEN combined with AZA regimen not only significantly improves treatment response rates in patients with HR-MDS but also effectively extends patient survival, with a favorable safety profile and overall manageable adverse reactions.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1072-1078"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Application of Next-Generation Sequencing Technology in Genetic Screening for Thalassemia in Zhangzhou Area].","authors":"Tian-You Li, Jie-Xiang Zheng, Wei-Rong Huang, Xiao-Hong Lai, Hua Wei, Shu-Rong Hong","doi":"10.19746/j.cnki.issn1009-2137.2026.04.021","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.021","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the application value of next-generation sequencing (NGS) in genetic screening for thalassemia in Zhangzhou area, clarify the characteristics of the local thalassemia gene carrier spectrum, and provide data support for regional precision prevention and control of thalassemia.</p><p><strong>Methods: </strong>A total of 1 130 individuals examined at the Medical Genetics Center of Zhangzhou Municipal Hospital of Fujian Province from June 2023 to December 2024 were enrolled. NGS was used to detect deletions, point mutations, and structural variations of globin genes.</p><p><strong>Results: </strong>Among the 1 130 samples, 326 thalassemia gene mutation carriers were identified, with an overall detection rate of 28.85% (326/1 130). Specifically, there were 262 cases (23.19%) of α-thalassemia, 52 cases (4.60%) of β-thalassemia, and 12 cases (1.06%) of α-thalassemia combined with β-thalassemia (αβ-thalassemia). A total of 56 rare globin gene mutations were detected, including 49 α-thalassemia mutations and 7 β-thalassemia mutations. Among them, <i>HBA2</i>:c.*93_*97delAAGTC and <i>HBA2</i>:c.*92_*97delinsTA were novel mutations. Additionally, 31 cases of abnormal hemoglobin involving 9 types were identified, among which <i>HBA1</i>:c.273G>T (Lys→Asn) was reported for the first time in Fujian Province.</p><p><strong>Conclusion: </strong>The thalassemia gene carrier spectrum in Zhangzhou area is complex and diverse. NGS can efficiently cover common, rare, and novel mutations, markedly overcoming the limitations of traditional detection technologies including gap-PCR and RDB. It provides reliable technical support for precision prevention and control of thalassemia and genetic counseling in this region.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1079-1084"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[High-Risk Factors for Transformation to Acute Myeloid Leukemia in Patients with Higher-Risk Myelodysplastic Syndromes Undergoing Hypomethylating Agents].","authors":"Yuan Zhang, Hong-Wei Jia, Jia-Yang Li, Jing-Jing Zhou, Tian-Lan Li, Jun-Xia Huang, Chun-Xia Mao, Shan-Shan Liu, Yu-Jie Xu, Yan Gao, Xian-Qi Feng","doi":"10.19746/j.cnki.issn1009-2137.2026.04.018","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.018","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the high-risk factors for transformation to acute myeloid leukemia (AML) in patients with higher-risk myelodysplastic syndromes (MDS) undergoing hypomethylating agents (HMA).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on higher-risk MDS patients who received at least two cycles of HMA-based therapy and had complete clinical data at the Affiliated Hospital of Qingdao University between January 2016 and May 2025. The clinical and molecular characteristics at initial diagnosis were analyzed to identify risk factors for leukemic transformation.</p><p><strong>Results: </strong>With a median leukemia-free survival (LFS) of 14.3 months (range: 1.5-125.6 months), 39 patients (31.2%) experienced transformation to AML. Compared to the non-transformation group, the transformation group had a significantly higher percentage of bone marrow blasts (10.7% <i>vs.</i> 7.7%, <i>P</i>=0.002), a higher red blood cell count (2.62×10¹²/L <i>vs.</i> 2.30×10¹²/L, <i>P</i>=0.047), and a higher lactate dehydrogenase level (341.5 U/L <i>vs.</i> 279.5 U/L, <i>P</i>=0.013). Significant differences were also observed in the distribution of WHO classification subtypes (<i>P</i>=0.018) and treatment regimens (<i>P</i>=0.029) between the two groups. At diagnosis, the transformation group exhibited a higher <i>TP53</i> variant allele frequency (VAF, <i>P</i>=0.016) and higher mutation rates of <i>TP53</i> (<i>P</i>=0.012) and <i>NRAS</i> (<i>P</i>=0.009). Multivariate Cox regression analysis identified the percentage of bone marrow blasts and mutations in <i>TP53</i> and <i>NRAS</i> were independent risk factors for leukemic transformation in MDS. Furthermore, bone marrow fibrosis grade, the <i>RUNX1</i> mutation rate, and complex karyotype were independent risk factors for overall survival.</p><p><strong>Conclusion: </strong>The bone marrow blast percentage, <i>TP53</i> and <i>NRAS</i> mutations are independent risk factors for AML transformation in higher-risk MDS patients undergoing HMA therapy, while bone marrow fibrosis grade, the <i>RUNX1</i> mutation rate, and complex karyotype are independent prognostic factors for OS.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1053-1063"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Practical Application of Gene-Matched Platelets in Patients with Immune Platelet Transfusion Refractoriness].","authors":"Ya-Ling Yang, Wang-Xia Li, Yuan-Yan Zhu, Ming-Di He, Gang Shen","doi":"10.19746/j.cnki.issn1009-2137.2026.04.033","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.033","url":null,"abstract":"<p><strong>Objective: </strong>To develop a personalized platelet transfusion strategy based on platelet genotyping, donor-specific antibody (DSA) avoidance, and donor-recipient cross-reactive group (CREG) compatibility grading for patients with immune platelet transfusion refractoriness (PTR).</p><p><strong>Methods: </strong><i>HLA-A</i> and <i>HLA-B</i> genotypes of both recipients and donors were determined using quantitative real-time PCR. Platelet-reactive antibody specificities were characterized by the Luminex xMAP^® single-antigen beads. The probability of obtaining a genotypically matched platelet unit was estimated from regional HLA-I antigen frequencies, antibody specificity profiles, and CREG compatibility grading. Transfusion efficacy was prospectively monitored using the 24-hour corrected count increment (CCI).</p><p><strong>Results: </strong>A total of 45 HLA-I antibodies were detected in the recipients, and 25 of them had a random mismatch probability of more than 1%. After DSA avoidance, 80.5% of the matches between the recipients and donors in the local platelet database achieved a CREG compatibility level of B2UX or above. The 24-hour CCI of 20 platelet genotyping transfusions was (18.71±9.99), and the platelet transfusion interval was (11.60 ± 9.96) d. Although the recipients were negative for HLA-A24 antibody, the 24-hour CCI of 3 transfusions was <4.5. Notably, 25% of serologically negative samples tested positive for HLA-I antibodies by confirmatory testing.</p><p><strong>Conclusion: </strong>A transfusion strategy combining DSA avoidance and CREG-compatible donor selection significantly improves platelet transfusion efficacy. Establishing individualized genotyping archives and implementing serial CCI surveillance help identify underlying causes of refractoriness, including HLA-incompatible alleles that are undetectable by routine DSA screening.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1160-1164"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Study on the Effects and Underlying Mechanisms of SGK3 in Regulating Platelet Function].","authors":"Qiu-Xia Huang, Xuan-Ding Zhou, Qing Li, Ke-Sheng Dai, Rong Yan","doi":"10.19746/j.cnki.issn1009-2137.2026.04.023","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.023","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of SGK3 on platelet function and the underlying molecular mechanisms using SGK3-specific degrader SGK3-PROTAC1.</p><p><strong>Methods: </strong>Western blot was used to detect SGK3 expression in human and mouse platelets, and to verify the degradation effect of SGK3-PROTAC1 on SGK3 protein. Platelets were pretreated with different concentrations of SGK3-PROTAC1, and platelet aggregation induced by the thromboxane A₂ analog U46619 and thrombin was measured using a platelet aggregometer. Flow cytometry was used to evaluate the integrin αⅡbβ3 activation, P-selectin expression, and phosphatidylserine (PS) exposure in platelets. Platelet spreading assay and clot retraction assay were conducted to evaluate the effects of SGK3-PROTAC1 on adhesion, spreading, and coagulation-related functions. A FeCl₃-induced mesenteric arterial thrombosis model was established, and tail bleeding time was measured to evaluate the effect of SGK3-PROTAC1 on arterial thrombosis. Finally, Western blot was used to detect the phosphorylation level of PKC substrate pleckstrin, so as to explore the downstream signaling pathway by which SGK3 regulates platelet function.</p><p><strong>Results: </strong>SGK3 was expressed in both human and mouse platelets. Treatment with SGK3-PROTAC1 markedly reduced SGK3 protein levels (<i>P</i> < 0.05). SGK3-PROTAC1 dose-dependently inhibited U46619-induced platelet aggregation, αⅡbβ3 activation, P-selectin expression, and PS exposure, but had no significant effect on the aforementioned indices induced by thrombin. Moreover, SGK3-PROTAC1 treatment did not alter platelet spreading on fibrinogen-coated surfaces or clot retraction efficiency. <i>in vivo</i>, experiments demonstrated that SGK3-PROTAC1 significantly delayed FeCl₃-induced mesenteric arterial thrombosis formation and markedly prolonged tail bleeding time in mice, while exerting no obvious effect on peripheral platelet counts. Mechanistic investigations revealed that SGK3-PROTAC1 inhibited U46619-induced phosphorylation of PKC substrate pleckstrin in platelets, but had no significant impact on thrombin-mediated enhancement of PKC activity.</p><p><strong>Conclusion: </strong>SGK3 participates in partial platelet activation processes by regulating the PKC signaling pathway, and may serve as a potential therapeutic target for platelet-related disorders.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1092-1100"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Study on the Effect of Treatment Regiman Combined with Ruxolitinib on MPN Patients with Myelofibrosis and the Influencing Factors of Mutated Gene Load].","authors":"Duo-Er Wu, Yao Zhang, Lu-Xi Song, Qi He, Jun-Ying Wu, You-Shan Zhao, Dong Wu, Chun-Kang Chang","doi":"10.19746/j.cnki.issn1009-2137.2026.04.019","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.019","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy of ruxolitinib combined regimen in the treatment of myeloproliferative neoplasm (MPN) with myelofibrosis (MF) and its effect on mutated gene load.</p><p><strong>Methods: </strong>The clinical data of 79 MPN patients with MF were retrospectively collected from the Department of Hematology of Shanghai Sixth People's Hospital from January 2022 to November 2024 to explore the effect of combined treatment with ruxolitinib, the change of mutated gene load after treatment, and the relationship between them.</p><p><strong>Results: </strong>Ruxolitinib combined with thalidomide, prednisone, androgen, interferon and other drugs could significantly improve the clinical symptoms of MF patients, shrink the spleen, and patients reaching spleen volume reduction of 35% (SVR35) accounted for 45.5% of all patients with splenomegaly. The <i>JAK2</i> mutation load was significantly reduced in patients treated with regular interferon alpha therapy. In patients with low <i>JAK2</i> mutation load, the presence or absence of high molecular risk mutation was the main factor affecting SVR35.</p><p><strong>Conclusion: </strong>Ruxolitinib combined with thalidomide, prednisone, androgen, interferon alpha and other drugs can improve the clinical symptoms of MPN patients with MF, shrink the spleen, and also have a positive effect on reducing the <i>JAK2</i> mutation load.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1064-1071"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Diagnostic Value of PD-1 in Distinguishing the Aberrant T Cells from Angioimmunoblastic T-cell Lymphoma and Lymphoid Variant of Hypereosinophilic Syndrome].","authors":"Juan Feng, Xiang-Qin Weng, Jing Wu","doi":"10.19746/j.cnki.issn1009-2137.2026.04.037","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.037","url":null,"abstract":"<p><strong>Objective: </strong>To explore the diagnostic significance of programmed death-1 (PD-1) expression in angioimmunoblastic T-cell lymphoma (AITL) and lymphoid variant of hypereosinophilic syndrome (L-HES).</p><p><strong>Methods: </strong>Flow cytometry was used to detect aberrant CD3^-CD4 ⁺ lymphocytes in bone marrow samples from 35 AITL and 13 L-HES patients, the level of PD-1 expression on these cells was analyzed, and the positivity rate was calculated. CD3 ⁺CD4 ⁺ lymphocytes of healthy volunteers were utilized as normal controls, the difference in PD-1 expression between CD3 ⁺CD4 ⁺ lymphocytes in normal controls and aberrant CD3^- CD4 ⁺ lymphocytes in patients was compared.</p><p><strong>Results: </strong>The positive rate of PD-1 expression in CD3^-CD4 ⁺ lymphocytes was significantly higher in the AITL group than that in the L-HES and normal control groups (both <i>P</i> <0.05), while there was no difference between L-HES group and normal control group (<i>P</i> >0.05). No significant difference in the positive rate of PD-1 expression between EBV- DNA ⁺ and EBV-DNA ^-patients in AITL group was observed (<i>P</i> >0.05).</p><p><strong>Conclusion: </strong>The level of PD-1 expression detected by flow cytometry can help distinguish AITL from L-HES.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1184-1188"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}